China-based Suzhou Ribo Life Science Co Ltd (HK:06938) and Sweden-based Ribocure Pharmaceuticals AB (together 'Ribo') announced on Wednesday the submission of a Phase 2 clinical trial application to the European Medicines Agency (EMA) for RBD1119, a siRNA based therapeutic for the treatment of coronary artery disease.

Ribo has been advancing multiple siRNA candidates in parallel across atrial fibrillation and venous thromboembolism, and has established an anticoagulation/antithrombotic pipeline.

This new submission for coronary artery disease represents a key milestone in Ribo's programme to advance innovative oligonucleotide-based therapies aimed at systematically addressing the root cause of thromboembolic diseases.